Globestar Therapeutics Quick Ratio (GSTC) starting from the third quarter 2024 to third quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Globestar Therapeutics Corporation  (GSTC)

Globestar Therapeutics's Quick Ratio

GSTC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2024, Quick Ratio fell to 0 a new company low.

Within Major Pharmaceutical Preparations industry 559 other companies have achieved higher Quick Ratio than Globestar Therapeutics in third quarter 2024. While Quick Ratio total ranking in the third quarter 2024 has deteriorated compared to the prior quarter from 0 to 5595.

Explain Quick Ratio?
How much Cash & cash equivalents GSTC´s has?
What are GSTC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GSTC Quick Ratio (Jun 30 2024)
Q3		 (Mar 31 2024)
Q2		 (Dec 31 2023)
Q1		 (Sep 30 2023)
Q4		 (Jun 30 2023)
Q3
Y / Y Current Liabilities Change 134.72 % 139.78 % 22.82 % 19.05 % -11.14 %
Y / Y Cash & cash equivalent Change - - - - -
Quick Ratio MRQ 0 - - - -
GSTC's Total Ranking # 5595 # 0 # 0 # 0 # 0
Seq. Current Liabilities Change 5.72 % 5.47 % 6.88 % 96.96 % 8 %
Seq. Cash & cash equivalent Change - - - - -



Quick Ratio third quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 560
Healthcare Sector # 1148
Overall Market # 5595


Quick Ratio Statistics
High Average Low
1.05 0.08 0
(Sep 30 2013)   (Jun 30 2022)




Financial Statements
Globestar Therapeutics's Current Liabilities $ 2 Millions Visit GSTC's Balance sheet
Globestar Therapeutics's Cash & cash equivalent $ 0 Millions Visit GSTC's Balance sheet
Source of GSTC's Sales Visit GSTC's Sales by Geography


Cumulative Globestar Therapeutics's Quick Ratio

GSTC's Quick Ratio for the trailling 12 Months

GSTC Quick Ratio

 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth 63.23 % 34.6 % 8.56 % 18.31 % 33.07 %
Y / Y Cash & cash equivalent TTM Growth -99.71 % - -98.8 % -72.17 % -66.43 %
Quick Ratio TTM 0 - 0 0 0
Total Ranking TTM # 4273 # 2245 # 3715 # 2920
Seq. Current Liabilities TTM Growth 18.47 % 21.57 % 6.97 % 5.95 % -2.31 %
Seq. Cash & cash equivalent TTM Growth - - -97.77 % -44.62 % -0.08 %

Quick ratio ranking by company, industry and sector >> Back to GSTC Financial Strength Comparisons >> Go to Compare GSTC Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the unchanged in Current Liabilities in the Q3 2024 to $1.71 millions, cumulative Quick Ratio